Clinical application research of non-biological artificial liver therapy primarily utilizing the DPMAS mode in treating pre-and early liver failure
摘要
目的 探索双重血浆分子吸附(DPMAS)为主的非生物型人工肝治疗前早期肝衰竭的临床应用价值.方法 回顾性分析西安医学院第一附属医院、西安国际医学中心肝病科、榆林市中医医院肝病科170例肝衰竭患者的临床资料,根据治疗方式不同分为DPMAS组(内科治疗联合DPMAS,前早期50例、中期50例、晚期20例)和对照组(内科治疗,50例).通过比较不同治疗方式及治疗时机(前早、中、晚期)、患者的肝肾功能、凝血功能、炎症水平、肝外并发症及生存率等,分析DPMAS用于前早期肝衰竭干预的可行性及临床获益程度.结果 与对照组相比,DPMAS能够显著改善前早期患者的相关指标:丙氨酸氨基转移酶[(70.32±29.40)比(146.94±46.53)U/L]、天冬氨酸氨基转移酶[(59.20±21.63)比(122.27±41.84)U/L]、总胆红素[(98.37±36.95)比(135.03±41.04)μmol/L]、肌酐[(61.30±12.82)比(66.80±7.82)μmol/L]、国际标准化比值(1.40±0.06)比(1.56±0.29)、凝血酶原活动度[(70.3±13.82)比(60.21±15.00)s]等肝肾功能和凝血指标(P<0.05);降低C-反应蛋白[(11.72±1.94)比(15.69±2.10)mg/L]、肿瘤坏死因子[(22.53±6.50)比(42.85±16.85)mg/L]、白细胞介素-6[(16.88±2.03)比(30.69±5.59)ng/L]等炎症因子水平(P<0.001)及肝性脑病发生率(0%比2%,P=0.016),提高患者12周、24周生存率(90%比80%,88%比76%,P=0.048、0.03).在不同分期对比中,经DPMAS治疗后,前早期患者肝肾功能、凝血及炎症指标改善程度显著优于中晚期(P<0.001),肝外并发症发生率更低(P<0.001),24周生存率显著高于中期和晚期(88%比60%比20%,P<0.001).结论 前早期肝衰竭是DPMAS为主的非生物型人工肝治疗的最佳时机,可有效改善患者肝肾功能、凝血及炎症状态,降低并发症风险,提高远期生存率.
Objective This study aimed to explore the clinical application value of non-biological artificial liver therapy primarily utilizing the double plasma molecular adsorption system(DPMAS)in treating pre-and early-stage liver failure.Methods Clinical materials of 170 patients,who were diagnosed with liver failure at the department of hepatology at the First Affiliated Hospital of Xi'an Medical University and Xi'an International Medical Center,as well as the Department of Hepatology at Yulin Traditional Chinese Medicine Hospital,were retrospectively collected and divided into DPMAS group(120 cases received medical treatment combined DPMAS,including 50 in pre-and early-stage,50 in middle stage,and 20 in the end stage)and control group(50 cases received medical treatment)according to their treatment.Then,the feasibility and clinical benefit degree of DPMAS were analyzed according to the indices of liver and kidney function,coagulation function,inflammatory levels,extrahepatic complications,and survival rates of patients between different groups and different stages.Results Compared with the control group,the DPMAS group could significantly ameliorate the indices of liver and kidney and coagulation function,including alanine aminotransferase[(70.32±29.40)vs.(146.94±46.53)](U/L),aspartate aminotransferase[(59.20±21.63)vs.(122.27±41.84)](U/L),total bilirubin[(98.37±36.95)vs.(135.03±41.04)](μmol/L),creatinine[(61.30±12.82)vs.(66.80±7.82)](μmol/L),international normalized ratio[(1.40±0.06)vs.(1.56±0.29)]and prothrombin activity[(70.3%±13.82%)vs.(60.21%±15.00%)](all P<0.05),reduce the inflammatory associated C-reactive protein[(11.72±1.94)vs.(15.69±2.10)](mg/L),tumor necrosis factor[(22.53±6.50)vs.(42.85±16.85)](mg/L),and interleukin-6[(16.88±2.03)vs.(30.69±5.59)](ng/L)(all P<0.001),and hepatic encephalopathy incidence(0%vs.2%,P=0.016),and improve the 12-week and 24-week survival rates(90%vs.80%,88%vs.76%,P=0.048,0.030)of patients with the pre-and early-stage liver failure.In the comparison of different stages,the improvement degrees of liver and kidney functions,coagulation and inflammatory indicators of patients in the pre-and early-stage after DPMAS treatment were significantly better than those in the middle and late stages(P<0.001),the incidence of extrahepatic complications was lower(P<0.001),and the 24-week survival rate was significantly higher than that in the middle stage and the late stage(88%vs.60%vs.20%,P<0.001).Conclusion Pre-and early-stage liver failure represents a priority time for the non-biological artificial liver mainly based on DPMAS in treating liver failure.It can effectively improve the liver and kidney functions,coagulation and inflammatory status of patients,reduce the risk of complications and increase the long-term survival rate.